Linezolid for the Treatment of Multidrug‐Resistant, Gram‐Positive Infections: Experience from a Compassionate‐Use Program
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Linezolid was provided for treatment of multidrug-resistant, gram-positive infections through a compassionate-use program. Patients (n=796) received 600 mg of linezolid intravenously or orally every 12 h (828 treatment courses). Bacteremia was present in 46% of infections, endocarditis was present in 10.6%, and line-related infections were present in 31.1%. Other infections included intraabdominal infections (15.1%), complicated skin and skin-structure infections (13.3%), and osteomyelitis (10.7%). Causative pathogens included vancomycin-resistant enterococci (66.3%) and methicillin-resistant staphylococci (22.1%). Clinical intent-to-treat (ITT) outcomes in the evaluable population were as follows: cure, 73.3%; failure, 6.8%; and indeterminate, 19.9%. Microbiological ITT outcomes in evaluable patients were as follows: cure, 82.4%; failure, 14.1%; and indeterminate, 3.5%. At the test of cure assessment, the clinical cure and microbiological success rates were 91.5% and 85.8%, respectively. The most common adverse events possibly related to linezolid use were gastrointestinal disturbances (9.8% of cases), thrombocytopenia (7.4% of cases), decreased hemoglobin/hematocrit levels (4.1% of cases), and cutaneous reactions (4.0% of cases). Linezolid provided high rates of clinical cure and microbiological success in this complicated patient population, with very good overall tolerance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Birmingham et al 202 reported cure in 17 of 22 courses of therapy (77%) for E faecium IE.”
Citations
Cites
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Linezolid resistance in a clinical isolate of Staphylococcus aureus
Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L., Moellering, R. C., & Ferraro, M. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05410-1 · Cited by 1,033
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
Gonzales, R. D., Schreckenberger, P. C., Graham, M. B., Kelkar, S., DenBesten, K., & Quinn, J. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04376-2 · Cited by 542
Stevens, D. L., Herr, D., Lampiris, H., Hunt, J. L., Batts, D. H., Hafkin, B., & the Linezolid MRSA Study Group (2002) · Clinical Infectious Diseases · doi:10.1086/340353 · Cited by 506
Self-citationIn vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.839 · Cited by 461
Hematologic Effects of Linezolid: Summary of Clinical Experience
Gerson, S. L., Kaplan, S. L., Bruss, J. B., Le, V., Arellano, F. M., Hafkin, B., & Kuter, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2723-2726.2002 · Cited by 443
Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions
Shinabarger, D. L., Marotti, K. R., Murray, R. W., Lin, A. H., Melchior, E. P., Swaney, S. M., Dunyak, D. S., Demyan, W. F., & Buysse, J. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2132 · Cited by 384
Vancomycin Resistance in Staphylococci
Srinivasan, A., Dick, J. D., & Perl, T. M. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.3.430-438.2002 · Cited by 285
Thrombocytopenia Associated with Linezolid Therapy
Attassi, K., Hershberger, E., Alam, R., & Zervos, M. J. (2002) · Clinical Infectious Diseases · doi:10.1086/338403 · Cited by 259
Slatter, J. G., Stalker, D. J., Feenstra, K. L., Welshman, I. R., BRUSS, J. B., Sams, J. P., Johnson, M. G., Sanders, P., Hauer, M. J., Fagerness, P. E., et al. (2001) · PubMed · Cited by 248
Research works printed but not linked: 8
- 2002, MMWR Morb Mortal Wkly Rep, 51, 565
- Stalker DJ, 1997, DC: American Society for Microbiology, 23
- Stalker DJ, Wajszczuk CP, Batts DH. Linezolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days [abstract A115]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:23.
- Wynalda MA, 2000, Drug Metab Dispos, 28, 1014
- Slatter JG, 2001, Drug Metab Dispos, 29, 1136
- Dresser LD, Birmingham MC, Karchmer AW, Rayner CR, Falvin SM, Schentag JJ. Results of treating infective endocarditis with linezolid [abstract 2239]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:5.
- Zurenko GE, Todd WM, Hafkin B, etal Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract 848]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1997:118.
- Forrest A, Rayner CR, Meagher AK, Birmingham MC, Schentag JJ. Pharmacostatistical modelling of hematologic effects of linezolid (L) in seriously-ill patients (pts) [abstract 283]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:5.
Cited by
Items 301–400 of 428
Bulitta, J. B., Fang, E., Stryjewski, M. E., Wang, W., Atiee, G. J., Stark, J. G., & Hafkin, B. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01400-23 · Cited by 6
Enterococcus: Antimicrobial Resistance in Enterococci Epidemiology, Treatment, and Control
Chen, A. Y., & Zervos, M. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-595-8_3 · Cited by 11
Clinical pharmacology of linezolid: an oxazolidinone antimicrobial agent
Tan, T. Q., & Yogev, R. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.4.479 · Cited by 6
Antibiotic Resistance of Non-pneumococcal Streptococci and Its Clinical Impact
Desai, N., Steenbergen, J. N., & Katz, D. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_2 · Cited by 8
McCarthy, M. W., Baker, T., Satlin, M. J., & Walsh, T. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-77674-3_15 · Cited by 7
[Linezolid: antibacterial activity, clinical efficacy and resistance].
Bourgeois‐Nicolaos, N., Piriou, O., Butel, M. J., & Doucet‐Populaire, F. (2006) · PubMed · Cited by 10
Sangita, K., Gupta, G. K., Pandey, A., & Singh, P. (2025) · Journal of Medical Society · doi:10.4103/jms.jms_156_24 · Cited by 5
Astigarraga, P. M. O., Garnacho‐Montero, J., Grau, S., Colomo, Ó. R., Palomar, M., Zaragoza, R., García-Paredes, P. M., Cerdá, E., & Álvarez-Lerma, F. (2007) · Farmacia Hospitalaria · doi:10.1016/s1130-6343(07)75407-7 · Cited by 5
Jahoda, D., Nyč, O., POKORNÝ, D., Landor, I., & Sosna, A. (2006) · Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca · doi:10.55095/achot2006/047 · Cited by 5
Endocarditis and Other Intravascular Infections
Levasseur, S. M., & Saiman, L. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40181-4.00037-2 · Cited by 7
Osteomyelitis: A Literature Review
Rawung, R., & Moningkey, C. (2019) · Jurnal Biomedik JBM · doi:10.35790/jbm.11.2.2019.23317 · Cited by 5
Preclinical toxicity evaluation of novel antibacterial contezolid acefosamil in rats and dogs
Wang, W., Li, Z., Gordeev, M. F., & Yuan, H. (2024) · Journal of Applied Toxicology · doi:10.1002/jat.4579 · Cited by 5
Hickey, E. J., Gill, C., Misura, A., Flattery, A., & Abruzzo, G. K. (2006) · Therapy · doi:10.2217/14750708.3.4.521 · Cited by 5
Antimicrobial resistance: is it really that bad?
Dowell, S. F. (2004) · Seminars in Pediatric Infectious Diseases · doi:10.1053/j.spid.2004.01.013 · Cited by 5
Emergence and management of drug-resistant enterococcal infections
Miller, W. R., Murray, B. E., & Arias, C. A. (2013) · Microbial Drug Resistance · doi:10.2217/ebo.12.357 · Cited by 5
Brickner, S. J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00223-6 · Cited by 5
Yang, Y., Hu, X., Ran, Y., Wang, H., Fu, P., Wan, P., Deng, Z., Lang, X., Wang, N., Sun, F., et al. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00874-7 · Cited by 4
Chan, A., Cross, J. T., He, Y. Q., Lippa, B., & Ryan, D. (2013) · Drug Discovery · doi:10.1002/9781118354483.ch10 · Cited by 4
Clinical Considerations in the Approach to Vancomycin-Resistant Enterococci: A Narrative Review
Beale, J. W., & Durward, M. (2022) · International Journal of Medical Students · doi:10.5195/ijms.2022.1010 · Cited by 4
Multidrug-Resistant Gram-Positive Bacterial Infections
Jung, Y., & Kim, H. B. (2015) · Korean Journal of Medicine · doi:10.3904/kjm.2015.88.5.487 · Cited by 5
Enterococcal Infections in Adults
Reyes, K., Zervos, M., & John, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_3 · Cited by 5
Palraj, R., Knoll, B. M., Baddour, L. M., & Wilson, W. R. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00083-7 · Cited by 4
Thảo, L. T. P., Duc, T. N., Mỹ, L. T., Hong, L. M., Hoan, B. V., Hung, V. Q., & Hai, P. D. (2024) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.18488 · Cited by 4
How best to deal with endocarditis
Morris, A. M. (2006) · Current Infectious Disease Reports · doi:10.1007/s11908-006-0030-8 · Cited by 5
Linezolid desensitization in a pediatric patient
Güvenir, H., Mısırlıoğlu, E. D., Toyran, M., & Kocabaş, C. N. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.05.023 · Cited by 4
Ikheloa, J. O., Inyang, N., Adelekun, A., & Agwu, E. (2015) · Special bacterial pathogens journal. · doi:10.61915/bpj.602334 · Cited by 3
Nigo, M., Hasbun, R., & Vigil, K. J. (2018) · OBM Transplantation · doi:10.21926/obm.transplant.1804023 · Cited by 3
Shi, X., Wu, Y., Ni, H., Guo, M., Cheng, Q., & Xu, Y. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128236536231010051130 · Cited by 3
MRSA: Resistenzmechanismen, Epidemiologie, Risikofaktoren, Prophylaxe, Therapie
Heizmann, P., Heizmann, W. R., & Hetzer, R. (2005) · Zeitschrift für Herz- Thorax- und Gefäßchirurgie · doi:10.1007/s00398-005-0486-0 · Cited by 3
Endocarditis and Other Intravascular Infections
Levasseur, S. M., & Saiman, L. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2702-9.00037-4 · Cited by 3
Rouveix, B. (2006) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2006.05.012 · Cited by 3
Cannon, J. P., Pachucki, C. T., Aneziokoro, C., & Lentino, J. R. (2006) · Infectious Diseases in Clinical Practice · doi:10.1097/01.idc.0000226868.52136.24 · Cited by 3
Oral Agents for the Treatment of Orthopedic Infections Caused by Methicillin-resistant Staphylococci
Kim, B.-N. (2011) · Infection and Chemotherapy · doi:10.3947/ic.2011.43.4.322 · Cited by 3
Bacteriemia e infecciones endovasculares por grampositivos: nuevas opciones terapéuticas
Almirante, B. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13123565 · Cited by 3
Pallasch, J., Takahashi, M., Taubert, K. A., Shulman, S. T., Burns, J. C., Falace, D. A., Newburger, J. W., Gewitz, H.-S., Tong, D., Steckelberg, J. M., et al. (2007) · Cited by 3
Zer, Y., Bayram, A., Akin, E., & Balcı, İ. (2011) · Gaziantep medical journal · doi:10.5455/gmj-30-2011-36 · Cited by 3
Holt, S. L., Thompson-Brazill, K. A., Sparks, E., & Lipetzky, J. (2016) · Critical Care Nurse · doi:10.4037/ccn2016475 · Cited by 5
Clinical Updates and Recent Developments in Neuro-Ophthalmology
Vuppala, A.-A. D., & Miller, N. R. (2019) · Springer eBooks · doi:10.1007/978-3-030-25389-9_8 · Cited by 3
Brickner, S. J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00301-1 · Cited by 3
Heimer, S. R., Morrison, D., & Gilmore, M. S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397169-2.00039-1 · Cited by 3
Prugger, V., Egner, S., Windhager, R., Mitteregger, M., Bertha, G., & Wenisch, C. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.09.008 · Cited by 3
New therapeutic agents for resistant Gram-positive infections
Ziglam, H. M., & Nathwani, D. (2003) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.1.4.655 · Cited by 3
THE CLINICAL IMPACT OF MULTIRESISTANT GRAM-POSITIVE MICROORGANISMS IN LONG-TERM CARE FACILITIES
Shadowen, R. D. (2004) · Journal of the American Medical Directors Association · doi:10.1016/s1525-8610(04)70049-3 · Cited by 3
Rohde, R. E. (2006) · Cited by 3
Islam, S. U. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18742-1.00054-3 · Cited by 2
Sakurai, N., Kawaguchi, H., Matsui, T., Nishiura, H., Kobayashi, K., Imoto, W., Shibata, W., Nakamura, Y., & Kakeya, H. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70124 · Cited by 2
Heintz, B. H., & Halilovic, J. (2010) · Hospital Pharmacy · doi:10.1310/hpj4512-916 · Cited by 2
Emergency Department Perspective on Methicillin-resistant Staphylococcus aureus
Singer, J., Dowler, M., & Bosscher, B. (2006) · Pediatric Emergency Care · doi:10.1097/01.pec.0000214595.16380.c1 · Cited by 2
Painful neuropathy with skin denervation after prolonged use of linezolid
Chao, C., Sun, H., Chang, Y., & Hsieh, S. (2009) · BMJ Case Reports · doi:10.1136/bcr.08.2008.0702 · Cited by 2
Antibiotic Resistance of Non-Pneumococcal Streptococci and Its Clinical Impact
Jalava, J., & Seppälä, H. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-595-8_2 · Cited by 2
The Old and New Treatment Options for Vancomycin-resistant Enterococcal Infections
Tünger, Ö. (2012) · ANKEM Dergisi · doi:10.5222/ankem.2012.215 · Cited by 5
A Clinician’s Guide to the Treatment of Vancomycin Resistant Enterococci Bacteremia and Endocarditis
Soule, D., & Climo, M. W. (2016) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-016-0082-8 · Cited by 2
Enterococci: Resistance Update and Treatment Options
Linden, P. K. (2007) · CRC Press eBooks · doi:10.1201/b15169-6 · Cited by 3
Rolston, K. V. I., & Segreti, J. C. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.07.007 · Cited by 2
Nuclear Medicine imaging of vertebral infections: role of radiolabelled biotin
Lazzeri, E. (2009) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 2
The Efficacy of Linezolid for Methicillin-resistant Staphylococcus aureus Infectious Endocarditis
Kuwabara, F., Hirate, Y., Mori, S., Takanohashi, A., Yagami, K., Usui, M., Miyata, Y., & Yoshikawa, M. (2009) · Japanese Journal of Cardiovascular Surgery · doi:10.4326/jjcvs.38.280 · Cited by 2
Treatment of Gram-positive bone and joint infection: authors' response
Darley, E. S. R., & MacGowan, A. P. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh461 · Cited by 2
Stein, G. E., Schooley, S. L., Kak, V., & Havlichek, D. H. (n.d.) · Cited by 2
Neurological and Psychiatric Side Effects of Antimicrobials
Bangert, M. K., & Hasbun, R. (2020) · Current clinical neurology · doi:10.1007/978-3-030-56084-3_3 · Cited by 1
Comparison of vancomycin sensitive and resistant enterococcal infection in children
Yakin, H., Acikalin, B., Demir, O. O., Aykaç, K., Hazırolan, G., Cengiz, A. B., & Özsürekçi, Y. (2026) · BMC Pediatrics · doi:10.1186/s12887-026-06808-4 · Cited by 1
Shinabarger, D. L., & Eliopoulos, G. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-180-2_22 · Cited by 1
Agents for the treatment of multidrug-resistant gram-positive endocarditis
Long, J. K. (2005) · Current Infectious Disease Reports · doi:10.1007/s11908-005-0055-4 · Cited by 1
Serotonin syndrome associated with linezolid
Jeon, D., Nam, Y., Kim, S.-H., Choi, W. J., Kim, E.-B., Lee, H.-W., Nam, H.-J., Song, J.-E., & Lee, S.-K. (2014) · Allergy Asthma & Respiratory Disease · doi:10.4168/aard.2014.2.4.310 · Cited by 1
Managing drug-resistant organisms in acute care
Nealy, K. L., McCarty, D. J., & Woods, J. A. (2016) · The Nurse Practitioner · doi:10.1097/01.npr.0000476376.57985.36 · Cited by 1
Ameliorative effect of Phoenix dactylifera on adverse effects of Linezolid in rats
Aziz, E. A. A., El-Nabtity, S., & Said, M. (2017) · Zagazig Veterinary Journal/Zagazig Veterinary Journal (Online) · doi:10.21608/zvjz.2017.29245 · Cited by 1
AMELIORATIVE EFFECT OF PHOENIX DACTYLIFERA ON ADVERSE EFFECTS OF LINEZOLID IN MALE ALBINO RATS
Said, M., Aziz, S. A., & El-Nabtity, S. (2019) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2019.v11s5.t0023 · Cited by 1
Recent advances in the treatment of infections due to resistant Staphylococcus aureus
Anstead, G. M., & Owens, A. D. (2005) · Current Opinion in Internal Medicine · doi:10.1097/00132980-200502000-00004 · Cited by 1
Maniga, N., Mogaka, G., Nyambane, L., & Eilu, E. (2015) · Special bacterial pathogens journal. · doi:10.61915/bpj.720270 · Cited by 1
Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis
Rahman, A., Chhabra, S., & Parkesh, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00034-0 · Cited by 1
Tratamiento de la artritis bacteriana
Sánchez, D. P., & Marras, C. (2006) · Seminarios de la Fundación Española de Reumatología · doi:10.1016/s1577-3566(06)75098-9 · Cited by 1
The recent evolution of therapeutic weapons against resistant Gram-positive microorganisms
Manfredi, R., & Calza, L. (2008) · Archivos Venezolanos de Farmacología y Terapéutica · Cited by 1
O'Connor, C. (2016) · University of Limerick Institutional Repository (University of Limerick) · doi:10.34961/6535 · Cited by 3
Gutierrez, K. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-7020-3468-8.50086-9 · Cited by 1
Clinical Aspects of Multi-Drug Resistant Enterococci
Contreras, G., & Arias, C. A. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1400-1_19
[Linezolid for the treatment of newborns infected with vancomycin-resistant Enterococcus faecium].
Berberián, G., Castro, G., Fistolera, S., Travaglianti, M., Lopardo, H. Á., Mastroianni, A., & Rosanova, M. T. (2009) · PubMed
Present and Emerging Therapies for the Treatment of Drug-resistant Infections: Focus on Linezolid
Souli, M. (2010) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s1571
Polineuropatía dolorosa secundaria a tratamiento prolongado con linezolid: a propósito de un caso
Villar, M. P. G., Arguedas, C. G., Lasaosa, S. S., & Blasco, P. C. (2012) · Neurología · doi:10.1016/j.nrl.2011.10.013
Antibiotics in the management of spinal postoperative wound infections
Fassett, D. R., & Brodke, D. S. (2004) · Seminars in Spine Surgery · doi:10.1053/j.semss.2004.09.004
Painful polyneuropathy secondary to prolonged treatment with linezolid: Presentation of a case
Villar, M. P. G., Arguedas, C. G., Lasaosa, S. S., & Blasco, P. C. (2012) · Neurología (English Edition) · doi:10.1016/j.nrleng.2012.08.003
Medications for Extensively Drug-Resistant Tuberculosis: Back to the Future?
Ashby, C. R., Jodlowski, T. Z., & Sym, D. (2008) · Journal of Pharmacy Technology · doi:10.1177/875512250802400205
Non-inferiority designs and novel antimicrobials
Tarchini, G., & Solomkin, J. S. (2014) · Clinical Investigation · doi:10.4155/cli.14.34
Emerging Treatments for Resistant Bacterial Infections and Pathogen-Focused Therapy
Rice, L. B., Bartlett, J. G., Craven, D. E., Stevens, D. L., Moellering, R. C., & Eliopoulos, G. M. (2008) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e318168c6f9
Management of infective endocarditis in children
Marwah, A., & Shrivastava, S. (2011) · Journal of Indian College of Cardiology · doi:10.1016/s1561-8811(11)80001-5 · Cited by 1
Ristori, C. A., Rowlands, R. E. G., Rowlands, G., Maria, A. R. A., Silva, G. I., Lopes, L., de Paula, A. M. R., Lima, C., Tegani, L. S., Watanabe, A. H., et al. (2012) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · doi:10.53393/rial.2012.71.32420
Adverse reactions to antibiotics in critical care
Brown, R. B., & Granowitz, E. V. (2008)
Managing drug-resistant organisms in acute care
Nealy, K. L., McCarty, D. J., & Woods, J. A. (2016) · Nursing Critical Care · doi:10.1097/01.ccn.0000482512.12788.30
Prävention und Antibiotikatherapie postoperativer Komplikationen
Lemmen, S., & Eckmann, C. (2011) · Springer eBooks · doi:10.1007/978-3-642-14223-9_19
BMJ Publishing Group Ltd.BMA House, Square, T., London, & 9JR, W. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.63123corr1
Chang, S. H., 김성우, Jeon, H. R., & 신정빈 (2015) · Jouranl of Korean Association of EMG Electrodiagnostic Medicine · doi:10.18214/jkaem.2015.17.1.40
Bradley, J. S., Cannavino, C. R., Franzon, D. E., & Duthie, S. E. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-07307-3.10094-1 · Cited by 2
Pérez, M. I. G. (2009) · Buleria (Universidad de León) · doi:10.18002/10612/785
Díaz, A. M. S. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Antimicrobial therapies for antimicrobial-resistant pathogens in urinary tract infections
Hamasuna, R., Matsumoto, T., & Suzuki, K. (2014) · doi:10.2217/fmeb2013.13.329
Anderson, R. J., Groundwater, P. W., Todd, A., & Worsley, A. J. (2012) · Wiley eBooks · doi:10.1002/9781118325421.ch11
Endovascular Infections and Endocarditis
Zingg, W., & Pittet, D. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_15
Chernyshоva, O. Y. (2020) · CHILD`S HEALTH · doi:10.22141/2224-0551.5.65.2015.74876
Bradley, J. S., Pong, A. L., Franzon, D. E., & Duthie, S. E. (2006) · Elsevier eBooks · doi:10.1016/b978-032301808-1.50090-0
Use of Linezolid in the treatment of surgical infectious complications under antibiotic resistance
Nazarchuk, O. A., Vitkovskiy, V. L., & Babina, Y. (2021) · Perioperaciina Medicina · doi:10.31636/prmd.v3i2.5
Approaches to vancomycin-resistant enterococci
Torres‐Viera, C., & Dembry, L. (2005) · Current Opinion in Internal Medicine · doi:10.1097/00132980-200502000-00003
Metadata
- Authors
- Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., & Schentag, J. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Kalamazoo Public Library (US)
- Corresponding author
- Schentag, Jerome J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-01-15
- Volume
- 36
- Issue
- 2
- Pages
- 159-168
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2153039659
- Semantic Scholar
- 884899ebe7caae27908d4715f8dc57cf1db6c0c1
- Cited by
- 428
- References
- 25
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 7 · 2021: 9 · 2020: 18 · 2019: 12 · 2018: 17 · 2017: 14 · 2016: 13 · 2015: 21 · 2014: 19 · 2013: 19 · 2012: 13
- FWCI
- 21.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- linezolid, compassionate use program, vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, bacteremia, endocarditis, osteomyelitis, complicated skin and skin structure infections, intra-abdominal infection, clinical cure, adverse events, drug tolerability
- MeSH terms
- Linezolid, Acetamides, Adolescent, Adult, Aged, Anti-Infective Agents, Drug Interactions, Female, Humans, Male, Middle Aged, Treatment Outcome, Gram-Positive Bacterial Infections, Drug Resistance, Multiple, Oxazolidinones, Drug Resistance, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.